This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

LAST CHANCE: REGISTER BY MAY 20 TO SAVE UP TO $300

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
June 14-16, 2022
Delivered as a Hybrid EventIntercontinental Mark Hopkins Hotel, San Francisco, California

Matthew Lorence
CEO at CDR3 Therapeutics Inc., USA

Profile

Matthew Lorence has extensive experience in the molecular diagnostic and genomics industries and is currently CEO at CDR3 Therapeutics, a UCLA startup focusing on virus-associated cancers and chronic viral infections. He most recently served as CEO at Concise Separations, as President and CEO of Edge Biosystems, and as SVP, Global Marketing at CalibreScientific. He earned both a PhD degree in Molecular Biology and an MBA degree in Marketing from the University of Texas at Dallas. Dr. Lorence has extensive experience with the FDA with broad knowledge of the CLIA regulations related to the development of LDTs.

Agenda Sessions

  • Stem Cell Delivered CARs

    4:30pm